PCSK9 inhibitors × lipids

TrialEuropean heart journal2022

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.

Kausik K Ray et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 203 people · 2022

Randomised comparison

Probably lowered lipids

−43.7percentage points−52.8 to −34.6

As reported

difference −43.7 %, 95% CI −52.8 to −34.6

Randomised comparison

Probably lowered lipids

−41.0percentage points−47.8 to −34.2

As reported

difference −41.0 %, 95% CI −47.8 to −34.2

Randomised comparison

Probably lowered lipids

−1.50mmol/L−1.80 to −1.20

As reported

difference −1.5 mmol/L, 95% CI −1.80 to −1.20

Randomised comparison

Probably lowered lipids

−1.30mmol/L−1.60 to −1.10

As reported

difference −1.3 mmol/L, 95% CI −1.60 to −1.10

Four numbers in the abstract

the abstract, start to end

LDL-C change with inclisiran was -43.7% [95% confidence interval (CI): -52.8 to -34.6] with a corresponding time-adjusted change of -41.0% (95% CI: -47.8 to -34.2); (P <

in LDL-C at Day 510 with inclisiran was -1.5 mmol/L (95% CI: -1.8 to -1.2), with a respective time-adjusted change of -1.3 mmol/L (95% CI: -1.6 to -1.1).

← favours treatmentfavours comparator →
could be chance
Lipids
−43.7−52.8 to −34.6
Lipids
−41.0−47.8 to −34.2
Lipids
−1.5−1.80 to −1.20
Lipids
−1.3−1.60 to −1.10
PCSK9 inhibitorsLipids

PCSK9 inhibitors × lipidshelps?settled

unlikelylikely
0.930.93 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

61 papers cite itlatest 60 shown

2022
2023
2024
2025
2026
this paperpooled itcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 36331315